Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease

BMC Immunology

Volumn 14, Issue 1, 2013, Pages

  Oka, Shomi ^a   Furukawa, Hiroshi ^a   Shimada, Kota ^a,b   Hayakawa, Hiromi ^a   Fukui, Naoshi ^a   Tsuchiya, Naoyuki ^c   Tohma, Shigeto ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Biomarker; Collagen disease; Cytokine; Interstitial lung disease

Indexed keywords

BIOLOGICAL MARKER; EOTAXIN 2; GELATINASE B; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; NEUTROPHIL COLLAGENASE; OSTEOPONTIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ACUTE ONSET DIFFUSE INTERSTITIAL LUNG DISEASE; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COLLAGEN DISEASE; DISEASE EXACERBATION; FEMALE; FIBROSING ALVEOLITIS; HUMAN; IMMUNOASSAY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; SURVIVAL;

ACUTE DISEASE; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COLLAGEN DISEASES; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOASSAY; LUNG DISEASES, INTERSTITIAL; MALE; TREATMENT OUTCOME;

EID: 84873584428     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-14-9     Document Type: Article

References (23)

1. Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004, 33:65-72. 10.1080/03009740310004621, 15163106.
2. Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J, Dixey J, Gough A, Prouse P, Winfield J, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology 2010, 49:1483-1489. 10.1093/rheumatology/keq035, 20223814.
3. Kameda H, Tokuda H, Sakai F, Johkoh T, Mori S, Yoshida Y, Takayanagi N, Taki H, Hasegawa Y, Hatta K, et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med 2011, 50:305-313. 10.2169/internalmedicine.50.4508, 21325762.
4. Ricou B, Nicod L, Lacraz S, Welgus HG, Suter PM, Dayer JM. Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996, 154:346-352.
5. Suga M, Iyonaga K, Okamoto T, Gushima Y, Miyakawa H, Akaike T, Ando M. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2000, 162:1949-1956.
6. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002, 3:409-421. 10.2174/1389203023380549, 12370004.
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
8. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088, Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347. 10.1056/NEJM197502132920706, 1090839.
10. Selman M, Ruiz V, Cabrera S, Segura L, Ramirez R, Barrios R, Pardo A. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?. Am J Physiol Lung Cell Mol Physiol 2000, 279:L562-L574.
11. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008, 5:e93. 10.1371/journal.pmed.0050093, 2346504, 18447576.
12. Fligiel SE, Standiford T, Fligiel HM, Tashkin D, Strieter RM, Warner RL, Johnson KJ, Varani J. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum Pathol 2006, 37:422-430. 10.1016/j.humpath.2005.11.023, 16564916.
13. Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C, Yousem S, Herrera I, Ruiz V, Selman M, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005, 2:e251. 10.1371/journal.pmed.0020251, 1198037, 16128620.
14. Kohan M, Puxeddu I, Reich R, Levi-Schaffer F, Berkman N. Eotaxin-2/CCL24 and eotaxin-3/CCL26 exert differential profibrogenic effects on human lung fibroblasts. Ann Allergy Asthma Immunol 2010, 104:66-72. 10.1016/j.anai.2009.11.003, 20143648.
15. Smith DR, Kunkel SL, Standiford TJ, Rolfe MW, Lynch JP, Arenberg DA, Wilke CA, Burdick MD, Martinez FJ, Hampton JN, et al. Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis. A compartmental analysis. Am J Respir Crit Care Med 1995, 151:1965-1973.
16. Vasakova M, Sterclova M, Kolesar L, Slavcev A, Pohunek P, Sulc J, Skibova J, Striz I. Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. Scand J Immunol 2009, 69:268-274. 10.1111/j.1365-3083.2008.02222.x, 19281539.
17. Homolka J, Ziegenhagen MW, Gaede KI, Entzian P, Zissel G, Muller-Quernheim J. Systemic immune cell activation in a subgroup of patients with idiopathic pulmonary fibrosis. Respiration 2003, 70:262-269. 10.1159/000072007, 12915745.
18. Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE, Matthay MA, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010, 299:L3-L7. 10.1152/ajplung.90637.2008, 2904092, 20418386.
19. Lewicki M, Kotyla P, Kucharz E. Increased adiponectin levels in women with rheumatoid arthritis after etanercept treatment. J Rheumatol 2009, 36:1346-1347. 10.3899/jrheum.081192, 19509093.
20. Andersen GN, Nilsson K, Pourazar J, Hackett TL, Kazzam E, Blomberg A, Waldenstrom A, Warner J, Rantapaa-Dahlqvist S, Mincheva-Nilsson L, et al. Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med 2007, 101:2199-2206. 10.1016/j.rmed.2007.04.019, 17643278.
21. Manetti M, Guiducci S, Romano E, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis 2012, 71:1064-1072. 10.1136/annrheumdis-2011-200837, 22258486.
22. Oikonomidi S, Kostikas K, Tsilioni I, Tanou K, Gourgoulianis KI, Kiropoulos TS. Matrix metalloproteinases in respiratory diseases: from pathogenesis to potential clinical implications. Curr Med Chem 2009, 16:1214-1228. 10.2174/092986709787846587, 19355880.
23. Ahn JK, Koh EM, Cha HS, Lee YS, Kim J, Bae EK, Ahn KS. Role of hypoxia-inducible factor-1alpha in hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes. Rheumatology (Oxford) 2008, 47:834-839.